Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Medical Solutions Group Regulatory News (AMS)

Share Price Information for Advanced Medical Solutions Group (AMS)

Share Price is delayed by 15 minutes
Get Live Data
219.00    2.00 (0.92%)
Bid:
218.50
Ask:
219.50
Spread: 1.00 (0.458%)
Market Cap: £475.74m
AMS Live PriceLast checked at - London Stock Exchange

Intraday Advanced Medical Solutions Group Share Chart

Rule 2.9 Announcement

8 Jun 2026 14:25

RNS Number : 4477H
Advanced Medical Solutions Grp PLC
08 June 2026
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

FOR IMMEDIATE RELEASE

8 June 2026

 

Advanced Medical Solutions Group plc("AMS")

 

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of The City Code on Takeovers and Mergers (the "Code"), AMS confirms that, as at the date and time of this announcement, it had 220,435,551 ordinary shares of 5 pence each in issue and admitted to trading on the AIM Market of the London Stock Exchange. AMS does not hold any ordinary shares in treasury. Therefore, the total number of shares with full voting rights in AMS at the above date was 220,435,551.

The International Securities Identification Number (ISIN) for AMS' ordinary shares is GB0004536594 and AMS' LEI number is 213800HJP6OWOSZI1L74.

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Tel: +44 (0) 1606 545508

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTUWUORNUUNRAR
Date   Source Headline
18th Mar 20257:00 amRNSDirectorate Change
14th Mar 20257:01 amRNSBlock listing Interim Review
14th Mar 20257:00 amRNSBlock listing Interim Review
28th Feb 20255:24 pmRNSTotal Voting Rights
31st Jan 20253:17 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNSFull Year 2024 Trading Update
31st Dec 202411:35 amRNSTotal Voting Rights
10th Dec 202410:37 amRNSHolding(s) in Company
29th Nov 20246:04 pmRNSTotal Voting Rights
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
1st Nov 202410:06 amRNSHolding(s) in Company
1st Nov 202410:05 amRNSTotal Voting Rights
18th Oct 20244:16 pmRNSHolding(s) in Company
11th Oct 20247:00 amRNSDirector/PDMR Shareholding
30th Sep 20245:02 pmRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
30th Aug 20244:53 pmRNSTotal Voting Rights
29th Aug 20247:00 amRNSNotice of Interim Results
31st Jul 20242:54 pmRNSTotal Voting Rights
15th Jul 20247:00 amRNSHalf Year Trading update
4th Jul 20247:00 amRNSClosing of Peters Surgical acquisition
1st Jul 202410:40 amRNSTotal Voting Rights
27th Jun 20247:00 amRNSRegulatory Approval for acquisition
12th Jun 20241:47 pmRNSResults of Annual General Meeting
12th Jun 20247:00 amRNSAnnual General Meeting
5th Jun 20248:42 amRNSHolding(s) in Company
3rd Jun 20245:27 pmRNSTotal Voting Rights
13th May 20245:53 pmRNSAnnual Report and Notice of Annual General Meeting
1st May 20249:10 amRNSTotal Voting Rights
26th Apr 20249:17 amRNSDirector/PDMR Shareholding
25th Apr 20243:41 pmRNSHolding(s) in Company
17th Apr 20243:30 pmRNSHolding(s) in Company
4th Apr 20243:17 pmRNSHolding(s) in Company
2nd Apr 20242:47 pmRNSDirector/PDMR and PCA Shareholding
28th Mar 20245:04 pmRNSTotal Voting Rights
18th Mar 202412:35 pmRNSDirector/PDMR Shareholding
13th Mar 20247:03 amRNSProposed acquisition of Peters Surgical
13th Mar 20247:03 amRNSUnaudited Preliminary Results
12th Mar 20247:00 amRNSBlock listing Interim Review
10th Jan 20247:00 amRNSFull Year Trading Update
30th Nov 20235:11 pmRNSTotal Voting Rights
31st Oct 20235:02 pmRNSTotal Voting Rights
25th Oct 20237:00 amRNSUS LiquiBand® distribution agreements signed
2nd Oct 20237:01 amRNSDirector/PDMR Shareholding
2nd Oct 20237:00 amRNSAppointment of New Chair
27th Sep 20235:55 pmRNSDirector/PDMR Shareholding
25th Sep 20233:15 pmRNSHolding(s) in Company
20th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSLiquiBand Fix8® US commercialisation agreement
14th Sep 20233:52 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.